11 assets in Dravet Syndrome

Therapeutic assets addressing Dravet Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)- Dravet Syndrome	The University of Texas Health Science Center, Houston	P4	BBB (78)
Bexicaserin Dravet Syndrome	Longboard Pharmaceuticals	P3	BB (68)
Rna, (P-Thio)[2?-O-(2-Methoxyethyl)](A-G-M?U-M?U-G-G-A-G-M?C-A-A-G-A-M?U-M?U-A-M?U-M?C) Dravet Syndrome	Stoke Therapeutics, Inc	P3	BB (68)
Clemizole Dravet Syndrome	Epygenix	P3	BB (64)
Soticlestat Dravet Syndrome	Takeda	P3	B (63)
Bmb-101 Dravet Syndrome	Bright Minds Biosciences Pty Ltd	P2	CCC (53)
etx101 Dravet Syndrome	Encoded Therapeutics	P1/2	CC (47)
ion337 Dravet Syndrome	Ionis Pharmaceuticals, Inc.	P1/2	CC (47)
Stiripentol Dravet Syndrome	Biocodex	P1	CC (46)
RC001 Dravet Syndrome	Second Affiliated Hospital of Guangzhou Medical University	Early P1	C (39)
P-MPPF Dravet Syndrome	Hospices Civils de Lyon	N/A	D (30)